MAPT and early-onset autosomal dominant Alzheimer disease: Considering the enhanced detrimental impact of hyperphosphorylated tau due to the P301L mutation, this protein could serve as a potential target for the advancement of therapeutic strategies for tauopathies including Alzheimer’s disease (AD), frontotemporal lobar degeneration with tau aggregates (FTLD-tau), and various other tau-related disorders.